immune checkpoint inhibitors

Research Reports

Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer

12/15/2021

Helmy M Guirgis, MD, PhD

Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.

Helmy M Guirgis, MD, PhD, aimed...

12/15/2021

Journal of Clinical Pathways

Videos

Neoadjuvant Immune Checkpoint Inhibitors Unlikely Cost-Effective for Muscle-Invasive Bladder Cancer

02/25/2021

Journal of Clinical Pathways

Videos

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

02/19/2021

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the...

02/19/2021

Journal of Clinical Pathways